ProofPilot is a technology company.
ProofPilot has raised $2.0M across 1 funding round.
ProofPilot has raised $2.0M in total across 1 funding round.
ProofPilot has raised $2.0M in total across 1 funding round.
ProofPilot's investors include UpVentures Capital, Jeffrey Wald.
ProofPilot is a New York-based SaaS company that builds an end-to-end clinical trial automation and engagement platform, enabling users to design, launch, and manage research studies digitally for virtual, hybrid, or in-person trials.[1][2][3] It serves life sciences companies, pharmaceutical firms like Eli Lilly, clinical sites, patients, and researchers by solving key pain points in clinical trials, such as protocol deviations, high dropout rates, recruitment inefficiencies, and lack of diversity through automated workflows, real-time task orchestration, micro-interactions, and integrations like wearable sensor tech.[1][2][3] The platform has demonstrated strong growth momentum, including $15.7M in total funding across 5 rounds, a 2023 Clinical Trials Arena Excellence Award for Business Expansion and Innovation, and proven results like a 67% cost reduction in a neuroscience study with <5% dropout and 90% diversity goals met.[1][2]
ProofPilot emerged from Cyclogram, a consulting firm founded by Matthew Amsden in 2005, evolving into a digital health startup in 2013-2014 with early platform versions supporting studies in the US, Brazil, and Peru.[3] Amsden founded ProofPilot formally in 2014, participating in the BluePrint Health Incubator that winter, but faced challenges from cultural disconnects in the venture-backed startup model, leading to a two-year customer pause and product relaunch in late 2017.[1][3] Leadership has transitioned over time: Chris Venezia became CEO in 2022, followed by indications of Brad Hightower (CEO of Hightower Clinical, a clinical research innovator) in recent company profiles, reflecting a focus on operational expertise in trials.[3][5][6] Pivotal early traction included global study support and a shift to progressive web apps for better user experience.[3]
ProofPilot rides the trend of digital transformation in clinical trials, accelerated by post-COVID demand for decentralized, hybrid models that reduce site burdens, improve patient retention, and incorporate wearables/AI for real-world evidence.[2][3] Timing is ideal amid regulatory pushes for diversity (e.g., FDA guidelines) and efficiency, with market forces like rising trial costs ($2.6B+ per drug) and 90%+ failure rates favoring automation platforms that cut deviations and enable global scale.[2] It influences the ecosystem by powering pharma partnerships (e.g., Lilly), supporting virtual/hybrid trials since 2014, and enabling non-experts to launch compliant studies, thus democratizing access and boosting innovation in drug development and digital health research.[1][2][3]
ProofPilot is poised to expand as a core infrastructure player in clinical trials, leveraging its automation stack for AI-enhanced wearables, predictive recruitment, and global DEI compliance amid a market projected to hit $50B+ by 2030. Trends like real-world data mandates and sensor tech will amplify its edge, potentially driving more Big Pharma integrations and acquisitions. Its evolution from bootstrapped relaunch to award-winning platform signals resilience, setting it to redefine high-performance trials—starting from that 2014 incubator spark into a efficiency revolution for life sciences.
ProofPilot has raised $2.0M across 1 funding round. Most recently, it raised $2.0M Seed in May 2016.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| May 1, 2016 | $2.0M Seed | UpVentures Capital, Jeffrey Wald |